⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4166672 | 0.96 | — | — | |
| SCHEMBL16573384 | 0.89 | — | — | |
| SCHEMBL26243152 | 0.87 | JAK1 (0.33) | — | |
| SCHEMBL19418300 | 0.87 | OPRL1 (0.30) | — | |
| SCHEMBL7854795 | 0.87 | JAK1 (0.33) | — | |
| SCHEMBL389800 | 0.86 | — | — | |
| SCHEMBL24003586 | 0.85 | — | — | |
| SCHEMBL7855601 | 0.85 | — | — | |
| SCHEMBL258670 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL3229473 | 0.81 | ADH1A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| WO-2021077031-A1 | COMPOUNDS AND METHODS TARGETING QSOX1 | SAPPHIRE BIOTECH, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020210380-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-101405270-A | Pyrazoles as 11-beta-HSD-1 | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009021945-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025668-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080119470-A1 | Neurologically-Active Compounds | XOMA TECHNOLOGY LTD. | 2008-05-22 | — | — | US | disclosed |
| US-20070275448-A1 | Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides | CSIR (ZA) | 2007-11-29 | — | — | US | disclosed |
| CN-101027286-A | Indazolone derivatives as 11 b-HSD 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | disclosed |
| CN-101018772-A | Neuroactive compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007027248-A2 | 3', 5' - CYCLIC NUCLEOSIDE ANALOGUES FOR TREATMENT OF HCV | VALEANT RESEARCH & DEVELOPMENT (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1737831-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Limited (AU) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005095360-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |